Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;221(2):172-8.
doi: 10.1159/000317775. Epub 2010 Jul 13.

Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial

Kristian Reich  1 , Jean-Paul Ortonne, Urs Kerkmann, Yanxin Wang, Jean-Hilaire Saurat, Kim Papp, Richard Langley, Christopher E M Griffiths
Affiliations

Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial

Kristian Reich et al. Dermatology. 2010.

Erratum in

  • Dermatology. 2011 Feb;222(1):4

Abstract

Background: The EXPRESS study demonstrated the initial efficacy of infliximab in psoriasis affecting the skin and nails.

Objective: To further assess how patients with a positive initial response to infliximab respond to 1 year of continuous infliximab treatment.

Methods: A retrospective analysis of patients with moderate-to-severe plaque and nail psoriasis who initiated and continued infliximab treatment up to week 46 was conducted.

Results: Among all nail psoriasis patients receiving 1 year of infliximab (n = 186), 74.6 and 54.1% achieved at least 75 or 90% improvement in the Psoriasis Area and Severity Index (PASI) at week 50. These PASI-75 (n = 138) and PASI-90 (n = 100) responders had respective mean improvements from baseline to week 50 of 93.6 and 97.3% for the PASI, 90.6 and 94.1% for the Dermatology Life Quality Index (DLQI) and 78.2 and 80.3% for the Nail Psoriasis Severity Index (NAPSI).

Conclusions: Infliximab treatment for 1 year produced sustained improvement in PASI, DLQI and NAPSI scores.

PubMed Disclaimer

Publication types